Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance.

Sections of formalin-fixed, paraffin-embedded tissues from 210 human breast cancers were immunohistochemically examined using the mAb against human tenascin (TN) RCB1. Immunoreactive TN was detected in the breast cancer stroma in 77 (36.7%) cases, whereas the remaining 133 (63.3%) were negative. Of the 77, 12 (5.7%) cases also showed positive staining in the carcinoma cell cytoplasm. The positive cells were often observed in the margin of the cancer nests at the site adjacent to the stroma. According to the staining pattern of TN, the breast cancer cases were classified into the three groups of cancer cell TN(+)/stromal TN(+), cancer cell(-)/stromal TN(+), and cancer cell(-)/stromal TN(-). Analysis of the relationship of these TN patterns with various clinicopathological characteristics of the tumors and the patient outcome revealed that, in comparison to the cancer cell(-)/stromal TN(-) group, the cancer cell TN(+)/stromal TN(+) group exhibited increased frequency of lymph node metastasis and exceptionally poor outcome, and the cancer cell(-)/stromal TN(+) group also showed more frequent metastasis and poorer outcome. Most of the cancer cell TN(+)/stromal TN(+) cases were c-erbB-2 positive and estrogen receptor negative. Furthermore, in situ hybridization of freshly obtained breast cancer tissues demonstrated that both cancer cells and stromal cells express TN mRNA. These results indicate that the TN in breast cancer is produced by cancer epithelial cells as well as by stromal mesenchymal cells, and that cancer cell TN might be involved in cancer spreading, resulting in unfavorable patient prognosis.

[1]  Y. Kawarada,et al.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Zardi,et al.  Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues , 1991, International journal of cancer.

[3]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.

[4]  R. Tucker.  The sequential expression of tenascin mRNA in epithelium and mesenchyme during feather morphogenesis , 1991, Roux's archives of developmental biology.

[5]  Matthias Chiquet,et al.  Tenascin interferes with fibronectin action , 1988, Cell.

[6]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[7]  M. Mottolese,et al.  Expression and production of tenascin in benign and malignant lesions of melanocyte lineage , 1990, International journal of cancer.

[8]  Ina Ruck,et al.  USA , 1969, The Lancet.

[9]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[10]  I. Virtanen,et al.  Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[11]  D. Steindler,et al.  Boundaries defined by adhesion molecules during development of the cerebral cortex: the J1/tenascin glycoprotein in the mouse somatosensory cortical barrel field. , 1989, Developmental biology.

[12]  D.,et al.  Regression Models and Life-Tables , 2022 .

[13]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[14]  J. Spring,et al.  Epithelial synthesis of tenascin at tips of growing bronchi and graded accumulation in basement membrane and mesenchyme. , 1991, Experimental cell research.

[15]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[16]  R. W. Scarff,et al.  Histological typing of breast tumors. , 1982, Tumori.

[17]  K. Koretz,et al.  Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma. , 1992, Gastroenterology.

[18]  R. Chiquet‐Ehrismann,et al.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis , 1986, Cell.

[19]  T. Sakakura,et al.  Tenascin in mammary gland development: from embryogenesis to carcinogenesis. , 1991, Cancer treatment and research.

[20]  H. Erickson,et al.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. , 1989, Annual review of cell biology.

[21]  M. Kusakabe,et al.  In situ hybridization with non-radioactive digoxigenin-11-UTP-labeled cRNA probes: localization of developmentally regulated mouse tenascin mRNAs. , 1991, The International journal of developmental biology.

[22]  G. Siegal,et al.  Tenascin expression in the human endometrium and in endometrial adenocarcinomas. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[23]  R. Chiquet‐Ehrismann.  Anti-adhesive molecules of the extracellular matrix. , 1991, Current opinion in cell biology.

[24]  I. Sugawara,et al.  Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. , 1991, Invasion & metastasis.

[25]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[26]  R. Hähnel,et al.  Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.

[27]  A. Bhattacharyya,et al.  Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. , 1991, Human pathology.

[28]  Y. Oike,et al.  Isolation and characterization of human fibroblast tenascin. An extracellular matrix glycoprotein of interest for developmental studies. , 1990, The International journal of developmental biology.

[29]  V. Lightner,et al.  Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. , 1994, Experimental cell research.

[30]  E. Wisse,et al.  Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. , 2008, Liver.

[31]  B. Gusterson,et al.  The distribution of immuno-reactive tenascin in the epithelial-mesenchymal junctional areas of benign and malignant squamous epithelia , 1990, Virchows Archiv. B, Cell pathology including molecular pathology.

[32]  W. Gullick,et al.  Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. , 1991, Cancer research.

[33]  P. Ekblom,et al.  Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions. , 1989, The International journal of developmental biology.

[34]  G. Edelman,et al.  Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization , 1990, The Journal of cell biology.

[35]  N. Hiraiwa,et al.  Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor. , 1993, Journal of cell science.

[36]  Y. Hamada,et al.  Tenascin staining positivity and the survival of patients with invasive breast carcinoma. , 1993, The Journal of surgical research.

[37]  P. Bornstein,et al.  Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. , 1991, The Journal of biological chemistry.

[38]  Y. Soini,et al.  Tenascin immunoreactivity in lung tumors. , 1993, American journal of clinical pathology.

[39]  M. Kusakabe,et al.  Can tenascin be redundant in cancer development? , 1994, Perspectives on developmental neurobiology.

[40]  H. Kawakatsu,et al.  Specific expression of tenascin in human colonic neoplasms. , 1993, British Journal of Cancer.

[41]  P. van Eyken,et al.  Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study. , 1990, Journal of hepatology.

[42]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[43]  L. Sobin,et al.  Histological Typing of Breast Tumors 1 , 1982 .

[44]  P. Humphrey,et al.  Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. , 1993, Human pathology.

[45]  M. Kusakabe,et al.  Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis. , 1988, Developmental biology.